Roivant Sciences(US:ROIV) ZACKS·2025-02-10 14:15分组1 - Roivant Sciences Ltd. reported a quarterly loss of $0.13 per share, better than the Zacks Consensus Estimate of a loss of $0.24, representing an earnings surprise of 45.83% [1] - The company has surpassed consensus EPS estimates three times over the last four quarters [2] - Montes Archimedes Acquisition posted revenues of $9.02 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 42.40%, but down from $37.14 million year-over-year [2] 分组2 - Montes Archimedes Acquisition shares have declined approximately 8% since the beginning of the year, while the S&P 500 has gained 2.5% [3] - The company's earnings outlook is mixed, with current consensus EPS estimates of -$0.22 on $43 million in revenues for the coming quarter and -$0.93 on $97.46 million in revenues for the current fiscal year [7] - The Medical - Biomedical and Genetics industry is currently ranked in the top 28% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8] 分组3 - The estimate revisions trend for Montes Archimedes Acquisition is mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6] - MannKind, another company in the same industry, is expected to report quarterly earnings of $0.03 per share, reflecting a year-over-year change of +50%, with revenues projected at $76.74 million, up 31.2% from the previous year [9]